4:20 pm : While gains remained moderate Monday, equities rebounded from sharp selling action that sunk Friday's market. Buyers eyed bargains left in the wake of last week's average 2.6% drop in the indices, and some positive news on the corporate front helped provide incentive to snatch them.
The ten economic sectors stood in�split fashion for most of the session. Despite retreats in prices across the energy complex, the Energy sector (+1.1%) managed to attract further buying interest and led the advancers. Oil services stocks�paved the way higher, as SLB enjoyed
Soda and Blood Pressure Colas with caffeine could play a role in high blood pressure, according to preliminary study findings.
more
General Health Tip
Picking the Best Canned Soup. Keep your eye on the total fat -- it should be no more than 3 grams. Some canned cream soups pack a whopping 25 grams. Others pour almost an entire day's worth of sodium in one can; if a can has more than 500mg of sodium, put it back.
More
JESSICA'S DIVA DEMANDS
Jessica Simpson, 25, likes to act clueless, but she can swing her celebrity weight like a pro. According to a studio source, weeks before the press tour for The Dukes of Hazzard began, "we were bombarded with a six-page pamphlet of demands for Jessica from the office of her dad, Joe Simpson." Among Jessica's requests: paid accommodations for her hairstylist and assistant in the same hotel as Jessica; a wardrobe budget estimated in the thousands of dollars; cases of Evian water; and paid private... •JEN FREAKS OVER ANGELINA'S NEW BABY •JULIA STILES, GWYNETH PALTROW AND MORE!
W.Va. Lawmakers Approve Mine Safety Rules Davitt McAteer, an expert on coal mining health and safety issues, testifies before the Senate Appropriations Labor Subcommittee about safety issues with the Sago coal mine in West Virginia where 12 miners perished this month, on Capitol Hill in Washington, Monday, Jan. 23, 2006. At left is Ben Hatfield, president and CEO of International Coal Group, owners of the Sago coal mine. McAteer discussed the need for mines to use modern safety equipment, like the underground sensor locator he holds and the digital two-way messaging device on the table. (AP Photo/J. Scott Applewhite)
1:59 pm PT Pactiv Corp reports $0.07 above consensus; guides Q1 and Y06 EPS in-line (PTV) 21.89 : Reports Q4 (Dec) earnings of $0.30 per share, $0.07 better than the Reuters Estimates consensus of $0.23; revenues rose 11.8% year/year to $741 mln vs the $704.9 mln consensus. Co issues in-line guidance for Q1, sees EPS of $0.19-0.23 vs. $0.19 consensus.�Co issues in-line guidance for FY06, sees EPS of $1.07-1.17 vs. $1.14 consensus.� Co sees 2006 sales growth of 6-8%.
1:46 pm PT Market Wrap : While gains remained moderate Monday, equities rebounded from sharp selling action that sunk Friday's market. Buyers eyed bargains left in the wake of last week's average 2.6% drop in the indices, and some positive news on the corporate front helped provide incentive to snatch them.
1:42 pm PT Boston Scientific announces positive results of its Express SD Renal stent study (BSX) 23.34 -0.35 : Co annoucnes positive results from its Renaissance trial, which was designed to study the safety and effectiveness of the Express SD Renal stent in the treatment of renal artery disease. The primary endpoint of the study is restenosis, or the re-narrowing of a previously stented vessel, at nine months. The restenosis rate was compared to a benchmark of 40% determined by a literature review of similar endpoints in patients undergoing balloon angioplasty of the renal artery. Dr. Rocha-Singh reported a restenosis rate of 21.3%, which was significantly lower than the 40% benchmark. "The Renaissance study provides critical insight into the occurrence and treatment of renal artery disease...Physicians have seen poor results treating this disease with a balloon alone, so it's gratifying to see an improved outcome when incorporating the Express SD Renal stent." "These results will be used by Boston Scientific to seek approval from the Food and Drug Administration to make the Express SD Renal stent available for use in the renal arteries," said John Pedersen, President of Boston Scientific's Peripheral Interventions business. Dr. Rocha-Singh also reported excellent safety results, with a Major Adverse Event rate of 10.5%, including no in-hospital events and no reported stent thromboses. In addition, he reported a low target lesion revascularization, or repeat procedures due to re-narrowing of the vessel, rate of 8.4%. The trial also demonstrated excellent follow- up success with 93 of the 100 patients having ultrasound performed at nine months post implantation of the stent.
Add Content
Change Layout
Change Colors
New mail
